hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06318169 id: BIO89-100-131 briefTitle: A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis) overallStatus: RECRUITING date: 2024-03-13 date: 2026-12 date: 2029-02 date: 2024-03-19 date: 2024-04-29 name: 89bio, Inc. class: INDUSTRY briefSummary: The study will assess the efficacy and safety of 2 dose regimens of pegozafermin for the treatment of liver fibrosis stage 2 or 3 in adult participants with MASH (previously known as nonalcoholic steatohepatitis \[NASH\]). conditions: Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 1050 type: ESTIMATED name: Pegozafermin name: Placebo measure: Proportion of Participants With at Least an Improvement of Fibrosis ≥1 Stage Without Worsening of MASH/NASH at Week 52 measure: Proportion of Participants With MASH/NASH Resolution Without Worsening of Fibrosis at Week 52 measure: Change From Baseline in Liver Fat as Assessed by Magnetic Resonance Imaging - Proton Density Fat Fraction (MRI-PDFF) at Week 52 measure: Change from Baseline in Alanine Aminotransferase (ALT) at Week 52 and Month 36 measure: Time to First Occurrence of Disease Progression as Measured by Composite of Protocol -Specified Clinical Events sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: 89bio Clinical Study Site status: RECRUITING city: Little Rock state: Arkansas zip: 72211-3859 country: United States name: 89bio Clinical Study Site role: CONTACT lat: 34.74648 lon: -92.28959 facility: 89bio Clinical Study Site status: RECRUITING city: Ocala state: Florida zip: 34471 country: United States name: 89bio Clinical Study Site role: CONTACT lat: 29.1872 lon: -82.14009 facility: 89bio Clinical Study Site status: RECRUITING city: Hermitage state: Tennessee zip: 37076 country: United States name: 89bio Clinical Study Site role: CONTACT lat: 36.19617 lon: -86.6225 facility: 89bio Clinical Study Site status: RECRUITING city: Wichita Falls state: Texas zip: 76301 country: United States name: 89bio Clinical Study Site role: CONTACT lat: 33.91371 lon: -98.49339 facility: 89bio Clinical Study Site status: RECRUITING city: Richmond state: Virginia zip: 23226-1925 country: United States name: 89bio Clinical Study Site role: CONTACT lat: 37.55376 lon: -77.46026 hasResults: False
nctId: NCT06318156 id: ZSLL-KY-2024-056-03 briefTitle: Exploring the Distribution Patterns and Infrared Characteristics of Force-sensitive Acupoints in Different Lumbar Nerve Segments in Patients With LDH Based on "Press Quickly" Theory overallStatus: RECRUITING date: 2022-01-01 date: 2025-01-01 date: 2025-01-01 date: 2024-03-19 date: 2024-03-19 name: Zhou Xingchen class: OTHER briefSummary: Utilizing the "responsive acupoint palpation" technique and infrared thermography, we investigated the distribution patterns of pressure-sensitive acupoints across different lumbar spinal segments in patients with lumbar disc herniation (LDH). Methodology: The Finger TPS tactile pressure measurement system was employed to conduct sensitivity examinations on the acupoints of the L1\~L5 lumbar spine in 80 LDH patients (Group 1) and 80 healthy individuals (Group 2), applying a standardized force of 60N. When a sensation of comfort was elicited, the points were marked on a human cutaneous nerve segment map. We then utilized infrared thermography to collect and compare the temperature differences of the top 10 most frequently responsive acupoint areas in the experimental group against those in the control group. conditions: Lumbar Disc Herniation studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: SCREENING masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 160 type: ESTIMATED name: Infrared thermal imaging measure: skin temperature sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: The Third Affiliated Hospital of Zhejiang Chinese Medical University status: RECRUITING city: Hangzhou state: Zhejiang zip: 310053 country: China name: Xingchen Zhou, Dr role: CONTACT phone: +86-18370133761 email: zhouxingchen0210@163.com lat: 30.29365 lon: 120.16142 hasResults: False
nctId: NCT06318143 id: U01HL168084 type: NIH link: https://reporter.nih.gov/quickSearch/U01HL168084 briefTitle: mAnaging siCkle CELl disEase Through incReased AdopTion of hydroxyurEa in Nigeria acronym: ACCELERATE overallStatus: NOT_YET_RECRUITING date: 2024-08 date: 2027-08 date: 2028-03 date: 2024-03-19 date: 2024-04-16 name: New York University class: OTHER briefSummary: Large knowledge gaps remain regarding strategies to promote the adoption of hydroxyurea (HU), particularly in sub-Saharan African countries including Nigeria, where more than 75% of annual sickle cell anemia births occur. The vast majority of people with SCD in Africa do not receive evidenced-based health care (e.g., newborn screening, health education, prophylaxis for infection, optimal nutrition and hydration, blood transfusion, transcranial Doppler screening, and HU therapy), despite its effectiveness in reducing SCD-related adverse outcomes and mortality. The use of HU in SSA is \<1% among SCD patients. The investigators' preliminary findings indicate that provider-level barriers are significant and must be addressed to improve HU adoption. To address HU adoption, the investigators will use the NIH-funded study (e.g., Realizing Effectiveness Across Continents with Hydroxyurea (REACH) Clinical Trial (NCT01966731)) that developed an evidence-informed, clinical, practical, and easy-to-follow algorithm to 1) Screen patients for sickle cell disease (SCD), 2) Initiate HU treatment, and 3) Maintain HU dosage over time (SIM) for the improved management of SCD as our intervention. The Nigerian government released guidelines supporting the SIM intervention for HU adoption for improved SCD management, and HU is on the list of essential medicines for Nigeria. The investigators' implementation strategy for improving SCD management in Nigeria uses a practical and replicable evidence-based task-sharing strategy, TAsk-Strengthening Strategy for Hemoglobinopathies (TASSH), adopted from the TAsk-Strengthening Strategy for Hypertension control (TASSH) trials in Ghana and Nigeria containing the essential components of i) Training healthcare workers/providers to be more patient-centered in clinical consultations, ii) Clinical reminders, and iii) Practice facilitation (TCP) known as (TASSH TCP) for SCD management. Using a sequential exploratory mixed-methods study design, the investigators will conduct this study using the Exploration, Preparation, Implementation, and Sustainment (EPIS) framework in four sequential phases to assess the effectiveness of SIM adoption by providers in the context of the TASSH TCP implementation strategy in Nigeria. conditions: Sickle Cell Disease studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: PARTICIPANT count: 900 type: ESTIMATED name: TASSH measure: Patient numbers - screening measure: Patient numbers - proportion on HU measure: Patient numbers - dosage measure: Mediators sex: ALL minimumAge: 9 Months stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06318130 id: LEAD-LBP briefTitle: Comparison of Pacing Lead Design on Left Bundle Branch Pacing Outcomes acronym: LEAD-LBP overallStatus: RECRUITING date: 2023-01-01 date: 2024-12-31 date: 2025-06-30 date: 2024-03-19 date: 2024-04-05 name: National University Hospital, Singapore class: OTHER briefSummary: This trial seeks to evaluate the performance of the extendable helix, stylet-driven pacing lead (EHL) compared to the fixed helix, lumenless pacing lead (FHL) during left bundle branch pacing (LBBP), with respect to enduring left bundle branch capture on follow-up, incidence of acute lead failure, pacing characteristics including QRS duration, pacing thresholds, R-wave amplitudes and lead impedance, and finally, safety profile during LBBP implantation. These data will guide future lead selection during LBBP implantation in achieving improved procedural success and optimal lead performance. conditions: Pacemaker DDD studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: A target of 210 participants will be enrolled in this study consisting of two groups and randomised in a 1:1 fashion to either of two groups.
Group 1: Fixed helix, lumenless pacing lead (FHL) Group 2: Extendable helix, stylet driven pacing lead (EHL) primaryPurpose: TREATMENT masking: TRIPLE maskingDescription: Subjects will be blinded to the type of pacing lead received. Operators will not be blinded as they will be performing the procedure. Post-procedure, investigators and outcomes assessors will be blinded to the treatment arm during adjudication of outcomes. whoMasked: PARTICIPANT whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 210 type: ESTIMATED name: Fixed helix, lumenless pacing lead. name: Extendable helix, stylet-driven pacing lead. measure: Incidence of loss of left bundle branch capture measure: Incidence of acute lead failure measure: Serial changes in pacing thresholds (V) measure: Serial changes in R-wave amplitude (mV) measure: Serial changes in lead impedance (ohm) measure: Serial changes in QRS duration (ms) measure: Incidence of peri-procedural complications sex: ALL minimumAge: 21 Years stdAges: ADULT stdAges: OLDER_ADULT facility: National University Heart Centre Singapore status: RECRUITING city: Singapore country: Singapore name: Eugene Tan, MBBS role: CONTACT phone: +6567795555 email: esjtan@nus.edu.sg lat: 1.28967 lon: 103.85007 hasResults: False
nctId: NCT06318117 id: 3398-1 briefTitle: Reason for Prescribing Rice Infant Formula overallStatus: NOT_YET_RECRUITING date: 2024-03-30 date: 2025-09-30 date: 2025-12-31 date: 2024-03-19 date: 2024-03-25 name: Mead Johnson Nutrition class: INDUSTRY name: BioFortis briefSummary: The main purpose of this study is to describe the pattern of RIF consumption in real life conditions, whatever the reasons of initiation and the chosen formula. The main objective is to study the reasons for prescribing a RIF during the first year of life, as per the pediatrician. Consumption started before 6 months of age, when milk and infantile formulas predominates in the baby's feeding, is of particular interest. conditions: Infant Formula studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: OTHER count: 120 type: ESTIMATED name: Rice infant formula measure: Questionnaire - reason for prescribing a RIF during the 1st year of life. measure: Questionnaire - Reason for prescribing a RIF in first 6 months of life measure: Questionnaire - Diet characteristics measure: Growth z-scores body mass index (BMI)-for-age measure: Growth z-score measure: Growth z-score measure: Growth z-score measure: Growth z-score measure: Questionnaire - Evolution of digestive and allergic symptoms measure: Socio-demographic characteristics sex: ALL minimumAge: 6 Months maximumAge: 11 Months stdAges: CHILD facility: Dr Christine REGIMBART - Private Practice city: Bécon-les-Granits state: Becon-les-Granits zip: 49026 country: France name: Christine Regimbart, MD role: CONTACT lat: 47.50134 lon: -0.8 facility: Centre Hospitalier d'Auxerre - Neonatology and pediatric emergency department city: Auxerre zip: 89011 country: France name: Bertrand Soto, MD role: CONTACT lat: 47.8 lon: 3.56667 facility: Centre Hospitalier Universitaire de Nantes - Pediatric emergency department city: Nantes zip: 44093 country: France name: Hugues Piloquet, MD role: CONTACT lat: 47.21725 lon: -1.55336 facility: Hôpital NOVO - Pediatric department city: Pontoise zip: 95300 country: France name: Mariana Englender, MD role: CONTACT lat: 49.05 lon: 2.1 hasResults: False
nctId: NCT06318104 id: DI/24/310/03/4 briefTitle: Efficacy and Safety of a Triple Eradication Scheme for Helicobacter Pylori Based on Tegoprazan vs Esomeprazole overallStatus: NOT_YET_RECRUITING date: 2024-04-19 date: 2024-11-29 date: 2025-02-28 date: 2024-03-19 date: 2024-03-19 name: Hospital General de México Dr. Eduardo Liceaga class: OTHER_GOV briefSummary: In Mexico, quadruple therapy is used to treat Helicobacter pylori (H.P.) at the expense of greater adverse effects, costs, and lower adherence to treatment. According to evidence, a competitive potassium channel blocker (P-CAB) is non-inferior to a proton pump inhibitor (PPI) and can improve the eradication rate of H.P. while maintaining triple therapy antibiotics (amoxicillin-clarithromycin) without increasing adverse effects, fewer drugs and better adherence to treatment. It is proposed to study the effect of a P-CAB in the eradication of H.P. as part of a triple therapy in Mexican patients, assuming that the efficacy and safety of a triple therapy of amoxicillin-clarithromycin-tegoprazan will be superior to amoxicillin-clarithromycin-esomeprazole. conditions: Helicobacter Pylori Infection studyType: INTERVENTIONAL phases: PHASE4 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: PARTICIPANT count: 160 type: ESTIMATED name: Tegoprazan name: Esomeprazole 40mg measure: Response to treatment by determining the eradication rate measure: Compared Treatment-related adverse events measure: Brief Medication Questionnaire measure: Percentage of patients with adherence to treatment measure: Report all Treatment-related adverse events sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06318091 id: MS.21.09.1640 briefTitle: Nanofat Versus Platelet Poor Plasma Gel for Infraorbital Rejuvenation overallStatus: COMPLETED date: 2021-06-01 date: 2023-06-01 date: 2023-06-01 date: 2024-03-19 date: 2024-03-19 name: Mansoura University class: OTHER briefSummary: this study was conducted for evaluation of the clinical efficacy, safety, and potential side effects of platelet poor plasma gel versus nonfat injection in infraorbital rejuvenation conditions: Tear Trough Eyelid Deformity studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: DOUBLE whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 60 type: ACTUAL name: platelet poor plasma gel name: nanofat measure: the degree of changes in the skin texture and homogeneity sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Manousra University, Faculty of Medicine city: Mansoura state: Dakahlia zip: 35511 country: Egypt lat: 31.03637 lon: 31.38069 hasResults: False
nctId: NCT06318078 id: UG2024001 briefTitle: Buikwe Electronic Community Health Information System Impact Study overallStatus: RECRUITING date: 2023-12-01 date: 2024-04 date: 2024-07 date: 2024-03-19 date: 2024-03-19 name: Malaria Consortium class: OTHER briefSummary: The purpose of the study is to investigate the impact of the eCHIS intervention on key child health outcomes. conditions: Malaria conditions: Diarrhea conditions: Pneumonia studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Cluster Randomised Control Trial primaryPurpose: HEALTH_SERVICES_RESEARCH masking: NONE count: 1140 type: ESTIMATED name: eCHIS measure: Out Patient Department attendance (due to malaria, pneumonia and diarrhoea) measure: Hospitalisation (due to malaria, pneumonia and diarrhoea) measure: malaria related mortality in the community and health facilities sex: ALL minimumAge: 3 Months maximumAge: 59 Months stdAges: CHILD facility: Buikwe status: RECRUITING city: Buikwe country: Uganda name: John Baptist Bwanika, MD role: CONTACT name: John Baptist Bwanika, MD role: PRINCIPAL_INVESTIGATOR lat: 0.3375 lon: 33.01056 hasResults: False
nctId: NCT06318065 id: B-ER111-370 briefTitle: Surgical Resection Outcomes in Patients With Brain Metastasis overallStatus: RECRUITING date: 2010-01-01 date: 2024-06-01 date: 2024-09-01 date: 2024-03-19 date: 2024-03-22 name: National Cheng-Kung University Hospital class: OTHER briefSummary: While many studies have investigated the prognostic factors for patients undergoing surgical resection for primary brain tumors, decision-making for patients with brain metastasis (BM) is more complex because of their higher burden of comorbidities compared to those with primary brain tumors. In addition, although various prognostic indicators have been identified to predict prognosis in several types of cancer, such as the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), prognostic nutritional index (PNI), and systemic immune-inflammation index (SII), limited studies have yet determined which group of patients would yield beater survival outcome after surgical resection for BM. This study aimed to investigate the impact of patient and perioperative characteristics and prognostic indicators on survival outcome of patients undergoing surgical resection of BM. conditions: Brain Metastases studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 100 type: ESTIMATED measure: survival outcome of patients undergoing surgery for brain metastasis measure: Functional outcome of patients undergoing surgery for brain metastasis sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Jung-Shun Lee status: RECRUITING city: Tainan state: None Selected zip: 70403 country: Taiwan name: Jung-Shun Lee, M.D. role: CONTACT phone: 886-6-2353535 phoneExt: 5181 email: nslee1218@gmail.com lat: 22.99083 lon: 120.21333 hasResults: False
nctId: NCT06318052 id: LUM-ABU-CO2-FemTouch-19-01 briefTitle: The Effect Of Fractional CO2 Laser Therapy On Cancer Survivors With Genitourinary Syndrome Of Menopause (GSM) overallStatus: RECRUITING date: 2019-11-01 date: 2024-11 date: 2024-11 date: 2024-03-19 date: 2024-03-20 name: Lumenis Be Ltd. class: INDUSTRY briefSummary: Improvement in cancer therapies has led to an increase in the number of women surviving chemotherapy (and other treatments) and overcoming cancer. This patient population presents specific clinical needs as chemotherapy (and other cancer treatments) treatment side effects can lead to early appearance of menopause symptoms and conventional hormonal treatments are contraindicated for these patients. The use of CO2 laser treatment has been shown to provide relief of Genitourinary Syndrome Of Menopause (GSM) symptoms in women and might provide a significant improvement in the quality of life for cancer survivors. The current study is designed to demonstrate the safety and efficacy of CO2 laser for treatment of GSM symptoms in cancer survivors suffering from GSM symptoms, with limited access to hormonal treatment. conditions: Vaginal Atrophy Patients With GSM studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 68 type: ESTIMATED name: The FemTouch delivery system name: Gynomunal gel treatment measure: To demonstrate the efficacy of fractionated CO2 laser treatments in cancer survivor patients with GSM as compared to the standard treatment measure: To demonstrate the efficacy of fractionated CO2 laser treatments in cancer survivor patients with GSM as compared to the standard treatment measure: To demonstrate the efficacy of fractionated CO2 laser treatments in cancer survivor patients with GSM as compared to the standard treatment. sex: FEMALE minimumAge: 21 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Frauenarztpraxis Heussweg status: RECRUITING city: Hamburg zip: 20255 country: Germany name: Matthias Theden-Scow, Dr role: CONTACT phone: 4210613 phoneExt: 040 email: dr.theden-schow@hamburg.de lat: 53.57532 lon: 10.01534 hasResults: False
nctId: NCT06318039 id: IRB2022-06554-01 briefTitle: Operation ACL: Rehabilitation After Anterior Cruciate Ligament Reconstruction overallStatus: NOT_YET_RECRUITING date: 2024-10-01 date: 2027-03-01 date: 2027-10-01 date: 2024-03-19 date: 2024-04-08 name: Linnaeus University class: OTHER briefSummary: Scientific Research Question
How should guidelines for rehabilitation after ACLR be structured, what should they include, and how should they be evaluated to best restore knee function in the patient? Can a detailed and comprehensive survey identify, explain, and prevent the risk factors causing a person to suffer from an ACL injury? conditions: Anterior Cruciate Ligament Reconstruction studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: randomized controlled trial primaryPurpose: TREATMENT masking: NONE count: 100 type: ESTIMATED name: Novel program name: Traditional program measure: Isokinetic muscle strength measure: Single-leg hop performance measure: Knee Injury and Osteoarthritis Outcome Score (KOOS) measure: ACL Return to Sport after Injury scale sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Linnaeus University city: Kalmar state: Sverige zip: 39363 country: Sweden lat: 56.66157 lon: 16.36163 hasResults: False
nctId: NCT06318026 id: R01AA031231 type: NIH link: https://reporter.nih.gov/quickSearch/R01AA031231 id: R01AA031231 type: NIH link: https://reporter.nih.gov/quickSearch/R01AA031231 briefTitle: Systematic Implementation of Patient-centered Care for Alcohol Use Trial: Beyond Referral to Treatment overallStatus: NOT_YET_RECRUITING date: 2024-07 date: 2029-02 date: 2029-02 date: 2024-03-19 date: 2024-03-20 name: Kaiser Permanente class: OTHER name: National Institute on Alcohol Abuse and Alcoholism (NIAAA) name: Kaiser Permanente Washington name: University of Washington briefSummary: The Systematic Implementation of Patient-centered Care for Alcohol Use Trial is a pragmatic, cluster-randomized, effectiveness-implementation trial testing two interventions to systematically implement shared decision-making with primary care patients with symptoms due to alcohol use: a primary care intervention and a centralized intervention. An anticipated 30 primary care clinics will be randomized to one of three conditions: usual care or the primary care or centralized interventions. conditions: Alcohol Use Disorder conditions: Unhealthy Alcohol Use studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: HEALTH_SERVICES_RESEARCH masking: SINGLE maskingDescription: EHR and survey (latter masked) whoMasked: OUTCOMES_ASSESSOR count: 1500 type: ESTIMATED name: Centralized Intervention name: Primary Care Intervention measure: Documentation of alcohol or substance use disorder treatment in the electronic health record (including insurance claims). measure: Continuous measure of change in alcohol use as documented on the AUDIT-C screening questionnaire. sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Kaiser Permanente Washington city: Seattle state: Washington zip: 98112 country: United States name: Megan Addis role: CONTACT phone: 206-287-2052 email: Megan.J.Addis@kp.org lat: 47.60621 lon: -122.33207 hasResults: False